anti enpp3 antibody drug conjugate ags 16c3f

Drug Overview

The treatment of advanced renal (kidney) cancers has been significantly enhanced by the development of “Smart Drugs” known as Antibody-Drug Conjugates (ADCs). anti enpp3 antibody drug conjugate ags 16c3f is a specialized ADC designed to deliver a potent cell-killing agent directly to cancer cells while minimizing exposure to healthy tissues.

This medication targets a specific protein that is found in high amounts on the surface of most kidney cancer cells. By acting as a precision-guided delivery system, AGS-16C3F represents a critical area of research for patients who have not responded to standard therapies. It combines the targeting power of an antibody with the destructive force of a chemotherapy-like toxin.

• Generic Name: Anti-ENPP3 Antibody-Drug Conjugate AGS-16C3F
• US Brand Names: None (Currently an Investigational Agent)
• Drug Class: Antibody-Drug Conjugate (ADC); Targeted Therapy
• Route of Administration: Intravenous (IV) Infusion
• FDA Approval Status: Investigational (Currently in Clinical Trials)

What Is It and How Does It Work? (Mechanism of Action)

Targeting ENPP3

The antibody portion of the drug is engineered to find and bind to ENPP3 (Ectonucleotide Pyrophosphatase/Phosphodiesterase 3). ENPP3 is a protein that is “overexpressed” (found in very high amounts) on the surface of Clear Cell Renal Cell Carcinoma (ccRCC) and papillary renal cell carcinoma cells. Crucially, this protein is not found in high amounts on most healthy adult cells.

Molecular Level Activity

1. Recognition: Once infused, AGS-16C3F circulates through the bloodstream until the antibody portion “locks” onto the ENPP3 receptor on a kidney cancer cell.
2. Internalization: The cancer cell pulls the drug inside itself through a process called endocytosis. The drug is now trapped within the cell.
3. Toxin Release: Inside the cell’s lysosomes (recycling centers), enzymes break the chemical linker, releasing the active toxin, MMAF.
4. Stopping Cell Division: MMAF is a tubulin inhibitor. It disrupts the internal “scaffolding” (microtubules) that the cell needs to divide and replicate. Without this scaffolding, the cancer cell cannot multiply and undergoes programmed cell death (apoptosis).

FDA-Approved Clinical Indications

Oncological Uses

AGS-16C3F is currently an investigational agent and is primarily being studied for:

• Advanced Renal Cell Carcinoma (RCC): Specifically for patients with metastatic clear cell or papillary kidney cancer who have already received other treatments (like tyrosine kinase inhibitors or immunotherapy).

Non-Oncological Uses

• There are currently no approved non-oncological uses for this medication.

Dosage and Administration Protocols

As an investigational drug, the exact dosage is determined by clinical trial protocols and is usually based on the patient’s body weight.

Export to Sheets

Dose Adjustments

• Renal/Hepatic Insufficiency: Because the toxin (MMAF) is processed by the liver, patients with liver impairment may require dose reductions. Specific guidelines for kidney impairment are still being established in ongoing trials.
• Ocular Toxicity: If changes in vision occur, the physician may delay the next dose or reduce the dosage.

Clinical Efficacy and Research Results

Clinical study data from the 2020–2025 period has focused on how well AGS-16C3F can stop cancer growth in patients who have run out of other options.

• Disease Control: In Phase 1 and 2 trials, researchers observed Stable Disease (SD) and Partial Responses (PR) in a segment of patients with metastatic renal cell carcinoma.
• Tumor Targeting: Studies confirmed that the drug successfully reaches ENPP3-positive tumors. Numerical data suggests that the higher the level of ENPP3 on the tumor, the more likely the patient is to respond to the treatment.
• Progression-Free Survival (PFS): While finalized long-term survival rates are still being gathered, preliminary results show that AGS-16C3F has a manageable safety profile that allows patients to remain on therapy for several months.

Safety Profile and Side Effects

The safety profile of AGS-16C3F is related to both the immune response to the antibody and the toxic effects of the MMAF payload.

Common Side Effects (>10%)

• Fatigue: A general sense of tiredness or low energy.
• Nausea: Mild stomach upset following the infusion.
• Peripheral Neuropathy: Numbness or tingling in the hands and feet.
• Blurred Vision: Temporary changes in eyesight.

Serious Adverse Events

• Ocular Toxicity (Keratopathy): Damage to the surface of the eye (cornea). This is a known side effect of ADCs using the MMAF toxin.
• Infusion-Related Reactions: Fever, chills, or difficulty breathing during the administration.
• Hepatotoxicity: Potential for elevated liver enzymes.
• Management: Eye drops and regular exams by an ophthalmologist are often required. Infusion reactions are managed with antihistamines and steroids.

Research Areas

Current research is exploring how AGS-16C3F can be combined with other Immunotherapies (such as PD-1 inhibitors). Scientists believe that by killing cancer cells, AGS-16C3F may release “signals” that help the immune system recognize the tumor more easily. There is also interest in determining if targeting ENPP3 can help eliminate “Cancer Stem Cells” in the kidney, which are often the cells responsible for the cancer coming back after initial treatment.

Patient Management and Practical Recommendations

Pre-Treatment Tests

• ENPP3 Expression Test: A biopsy review to confirm the tumor has the ENPP3 target.
• Eye Exam: A baseline vision test by an eye specialist is essential.
• Liver Function Panel: Baseline blood work to check liver health.

Precautions During Treatment

• Eye Care: Use prescribed lubricating eye drops and avoid wearing contact lenses if instructed.
• Neuropathy Monitoring: Report any new “pins and needles” sensations in your fingers or toes immediately.

Do’s and Don’ts

• DO report any changes in vision or eye pain to your oncology team right away.
• DO stay well-hydrated to help your body process the medication.
• DON’T ignore a fever or severe shivering during or after your infusion.
• DON’T start any new over-the-counter medications without checking with your oncologist first.

Legal Disclaimer

The content provided in this guide is for informational and educational purposes only and is not intended to serve as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, oncologist, or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide. AGS-16C3F is an investigational drug available only through clinical trials.